In vitro models of the crosstalk between multiple myeloma and stromal cells recapitulate the mild NF-κB activation observed in vivo
Multiple myeloma (MM) is linked to chronic NF-κB activity in myeloma cells, but this activity is generally considered a cell-autonomous property of the cancer cells. The precise extent of NF-κB activation and the contributions of the physical microenvironment and of cell-to-cell communications remain largely unknown. By quantitative immunofluorescence, we found that NF-κB is mildly and heterogeneously activated in a fraction of MM cells in human BMs, while only a minority of MM cells shows a strong activation. To gain quantitative insights on NF-κB activation in living MM cells, we combined advanced live imaging of endogenous p65 Venus-knocked-in in MM.1S and HS-5 cell lines to model MM and mesenchymal stromal cells (MSCs), cell co-cultures, microfluidics and custom microbioreactors to mimic the 3D-interactions within the bone marrow (BM) microenvironment. We found that i) reciprocal MM-MSC paracrine crosstalk and cell-to-scaffold interactions shape the inflammatory response in the BM; ii) the pro-inflammatory cytokine IL-1β, abundant in MM patients' plasma, activates MSCs, whose paracrine signals are responsible for strong NF-κB activation in a minority of MM cells; iii) IL-1β, but not TNF-α, activates NF-κB in vivo in BM-engrafted MM cells, while its receptor inhibitor Anakinra reduces the global NF-κB activation. We propose that NF-κB activation in the BM of MM patients is mild, restricted to a minority of cells and modulated by the interplay of restraining physical microenvironmental cues and activating IL-1β-dependent stroma-to-MM crosstalk.
Authors
- Federica Colombo (ORCID: https://orcid.org/0000-0001-9497-0240)
- Maurilio Ponzoni (ORCID: https://orcid.org/0000-0002-0055-325X)
- Marco Emilio Bianchi (ORCID: https://orcid.org/0000-0002-5329-6445)
- Marina Ferrarini (ORCID: https://orcid.org/0000-0003-1015-9632)
- A Agresti (ORCID: https://orcid.org/0000-0001-5006-9506)
- Francesca Brambilla (ORCID: https://orcid.org/0000-0001-9982-6133)
- Marco Rasponi (ORCID: https://orcid.org/0000-0002-2904-8652)
- Anna Sofia Tascini (ORCID: https://orcid.org/0000-0001-5731-5490)
- Francesca Mercalli (ORCID: https://orcid.org/0000-0003-0818-4660)
- Virginia Guzzeloni (ORCID: https://orcid.org/0000-0001-8258-1379)
- Cise Kizilirmak (ORCID: https://orcid.org/0000-0003-4837-3749)
- Elisabetta Ferrero (ORCID: https://orcid.org/0000-0003-2571-933X)
- Federica Moalli (ORCID: https://orcid.org/0000-0002-8426-2571)
- José Manuel García-Manteiga (ORCID: https://orcid.org/0000-0002-5481-040X)
- Samuel Zambrano (ORCID: https://orcid.org/0000-0002-9384-2017)
- Rosanna Mezzapelle (ORCID: https://orcid.org/0000-0002-1271-8998)
- Roberta Visone (ORCID: https://orcid.org/0000-0001-9077-1922)
Institutions
- Vita-Salute San Raffaele University (IT)
- IRCCS Ospedale San Raffaele (IT)
- Politecnico di Milano (IT)
Publication Details
- Journal
- Cell Death and Disease
- Published
- 2024-10-06
- DOI
- https://doi.org/10.1038/s41419-024-07038-1
- Citations
- 1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.24
Funders
- Fondazione Cariplo
- Associazione Italiana per la Ricerca sul Cancro